Daiichi Sankyo Co Ltd
TSE:4568
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3 825
6 148
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Daiichi Sankyo Co Ltd
Daiichi Sankyo Co Ltd
Other Current Liabilities
Daiichi Sankyo Co Ltd
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Other Current Liabilities
¥140.7B
|
CAGR 3-Years
41%
|
CAGR 5-Years
25%
|
CAGR 10-Years
8%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Other Current Liabilities
¥1.3T
|
CAGR 3-Years
0%
|
CAGR 5-Years
3%
|
CAGR 10-Years
11%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Other Current Liabilities
¥373.1B
|
CAGR 3-Years
15%
|
CAGR 5-Years
13%
|
CAGR 10-Years
6%
|
|
|
S
|
Shionogi & Co Ltd
TSE:4507
|
Other Current Liabilities
¥96.9B
|
CAGR 3-Years
8%
|
CAGR 5-Years
13%
|
CAGR 10-Years
7%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Other Current Liabilities
¥150.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
15%
|
CAGR 10-Years
14%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Other Current Liabilities
¥651.1B
|
CAGR 3-Years
26%
|
CAGR 5-Years
18%
|
CAGR 10-Years
16%
|
|
Daiichi Sankyo Co Ltd
Glance View
Daiichi Sankyo Co., Ltd., a prominent player in the global pharmaceuticals sector, has cemented its position as a leader through innovation and strategic expansion. Founded in 2005 from the merger of Daiichi Pharmaceutical and Sankyo Company, the company has continually focused on research and development, particularly in the fields of oncology, cardiovascular medicine, and vaccines. This dedication has resulted in a robust pipeline of transformative therapies, including the highly anticipated antibody-drug conjugates that address unmet medical needs. Investors are drawn to Daiichi Sankyo not just for its impressive portfolio but also for its commitment to quality and sustainability, underpinned by a strong financial foundation that supports ongoing growth. As the global healthcare landscape evolves, Daiichi Sankyo is well-prepared to adapt and capitalize on emerging opportunities, such as the accelerating demand for personalized medicine and innovative treatment modalities. The company's strategic partnerships and collaborations, particularly with international giants, have further bolstered its reach and resource capacity, making it a formidable force in the industry. For investors, this dynamic blend of innovative prowess, strategic foresight, and sound financial management makes Daiichi Sankyo an attractive option, promising potential long-term growth as it continues to push the boundaries of what's possible in healthcare.
See Also
What is Daiichi Sankyo Co Ltd's Other Current Liabilities?
Other Current Liabilities
140.7B
JPY
Based on the financial report for Sep 30, 2024, Daiichi Sankyo Co Ltd's Other Current Liabilities amounts to 140.7B JPY.
What is Daiichi Sankyo Co Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
8%
Over the last year, the Other Current Liabilities growth was 121%. The average annual Other Current Liabilities growth rates for Daiichi Sankyo Co Ltd have been 41% over the past three years , 25% over the past five years , and 8% over the past ten years .
You don't have any saved screeners yet
